Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C16H23NO2 |
| Molecular Weight | 261.3593 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CNC1CCCCC1)OC(=O)C2=CC=CC=C2
InChI
InChIKey=DKLKMKYDWHYZTD-UHFFFAOYSA-N
InChI=1S/C16H23NO2/c1-13(12-17-15-10-6-3-7-11-15)19-16(18)14-8-4-2-5-9-14/h2,4-5,8-9,13,15,17H,3,6-7,10-12H2,1H3
| Molecular Formula | C16H23NO2 |
| Molecular Weight | 261.3593 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Hexylcaine hydrochloride, a benzoic acid ester, is a local anaesthetic that has been used for surface anaesthesia of mucous membranes. Local anesthetics produce a transient block of nerve conduction by interfering with sodium channels. This effect of the anesthetic interferes with the development of an action potential across the nerve.
Originator
Sources: http://pubs.acs.org/doi/abs/10.1021/ja01237a010 | https://www.google.ch/patents/US2486374
Curator's Comment: refrence retrieved from http://www.drugfuture.com/chemdata/hexylcaine-hydrochloride.html
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | CYCLAINE Approved UseHexylcaine hydrochloride, a benzoic acid ester, is a local anaesthetic that has been used for surface anaesthesia of mucous membranes.
Local anesthetics produce a transient block of nerve conduction by interfering with sodium channels. This effect of the anesthetic interferes with the development of an action potential across the nerve. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
205 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/693515/ |
5 mL single, intrathecal dose: 5 mL route of administration: Intrathecal experiment type: SINGLE co-administered: |
HEXYLCAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
13 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/693515/ |
5 mL single, intrathecal dose: 5 mL route of administration: Intrathecal experiment type: SINGLE co-administered: |
HEXYLCAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A comparison in rat and mouse heart of the ability of several local anesthetics to inhibit monoamine oxidase. | 1983 |
|
| [Experience in the use of Osmocaine (hexylcaine) as a new local anesthetic in otorhinolaryngology]. | 1961-11 |
|
| Topical anesthesia with hexylcaine (cyclaine) for major endoscopic procedures; evaluation and comparison in 1,732 administrations. | 1956-04-28 |
|
| The clinical use of cyclaine (hexylcaine) as an anesthetic agent in urological surgery: a report of observations of 1000 patients. | 1954-08 |
|
| NEW AND nonofficial remedies: hexylcaine hydrochloride. | 1954-07-03 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:20:33 GMT 2025
by
admin
on
Mon Mar 31 18:20:33 GMT 2025
|
| Record UNII |
511IU0826Z
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C245
Created by
admin on Mon Mar 31 18:20:33 GMT 2025 , Edited by admin on Mon Mar 31 18:20:33 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB00473
Created by
admin on Mon Mar 31 18:20:33 GMT 2025 , Edited by admin on Mon Mar 31 18:20:33 GMT 2025
|
PRIMARY | |||
|
HEXYLCAINE
Created by
admin on Mon Mar 31 18:20:33 GMT 2025 , Edited by admin on Mon Mar 31 18:20:33 GMT 2025
|
PRIMARY | |||
|
274
Created by
admin on Mon Mar 31 18:20:33 GMT 2025 , Edited by admin on Mon Mar 31 18:20:33 GMT 2025
|
PRIMARY | |||
|
100000083962
Created by
admin on Mon Mar 31 18:20:33 GMT 2025 , Edited by admin on Mon Mar 31 18:20:33 GMT 2025
|
PRIMARY | |||
|
26879
Created by
admin on Mon Mar 31 18:20:33 GMT 2025 , Edited by admin on Mon Mar 31 18:20:33 GMT 2025
|
PRIMARY | RxNorm | ||
|
C004954
Created by
admin on Mon Mar 31 18:20:33 GMT 2025 , Edited by admin on Mon Mar 31 18:20:33 GMT 2025
|
PRIMARY | |||
|
DTXSID1047863
Created by
admin on Mon Mar 31 18:20:33 GMT 2025 , Edited by admin on Mon Mar 31 18:20:33 GMT 2025
|
PRIMARY | |||
|
7196
Created by
admin on Mon Mar 31 18:20:33 GMT 2025 , Edited by admin on Mon Mar 31 18:20:33 GMT 2025
|
PRIMARY | |||
|
532-77-4
Created by
admin on Mon Mar 31 18:20:33 GMT 2025 , Edited by admin on Mon Mar 31 18:20:33 GMT 2025
|
PRIMARY | |||
|
1373
Created by
admin on Mon Mar 31 18:20:33 GMT 2025 , Edited by admin on Mon Mar 31 18:20:33 GMT 2025
|
PRIMARY | |||
|
CHEMBL1197
Created by
admin on Mon Mar 31 18:20:33 GMT 2025 , Edited by admin on Mon Mar 31 18:20:33 GMT 2025
|
PRIMARY | |||
|
SUB08043MIG
Created by
admin on Mon Mar 31 18:20:33 GMT 2025 , Edited by admin on Mon Mar 31 18:20:33 GMT 2025
|
PRIMARY | |||
|
511IU0826Z
Created by
admin on Mon Mar 31 18:20:33 GMT 2025 , Edited by admin on Mon Mar 31 18:20:33 GMT 2025
|
PRIMARY | |||
|
10770
Created by
admin on Mon Mar 31 18:20:33 GMT 2025 , Edited by admin on Mon Mar 31 18:20:33 GMT 2025
|
PRIMARY | |||
|
C65852
Created by
admin on Mon Mar 31 18:20:33 GMT 2025 , Edited by admin on Mon Mar 31 18:20:33 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |